Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Reexamination Certificate
2007-06-12
2007-06-12
Andres, Janet L. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
C424S085400, C424S085500, C424S185100, C435S069510
Reexamination Certificate
active
10130084
ABSTRACT:
A conjugate exhibiting interferon gamma activity and comprising at least one first non-polypeptide moiety covalently linked to an IFG polypeptide, the polypeptide comprising an amino acid sequence that differs from that of a parent IFNG polypeptide in at least one introduced and/or at least one removed amino acid residue comprising an attachment group for the non-polypeptide moiety. The conjugate may be used for treatment of various diseases.
REFERENCES:
patent: 4457867 (1984-07-01), Ishida
patent: 4588585 (1986-05-01), Mark et al.
patent: 4604284 (1986-08-01), Kung et al.
patent: 4695623 (1987-09-01), Stabinsky
patent: 4727138 (1988-02-01), Goeddel et al.
patent: 4758656 (1988-07-01), Itoh et al.
patent: 4762791 (1988-08-01), Goeddel et al.
patent: 4832959 (1989-05-01), Engels et al.
patent: 4835256 (1989-05-01), Taniguchi et al.
patent: 4845196 (1989-07-01), Cowling
patent: 4855238 (1989-08-01), Gray et al.
patent: 4897471 (1990-01-01), Stabinsky
patent: 4898931 (1990-02-01), Itoh et al.
patent: 4904584 (1990-02-01), Shaw
patent: 4921698 (1990-05-01), Shirai et al.
patent: 4925793 (1990-05-01), Goeddel et al.
patent: 4929554 (1990-05-01), Goeddel et al.
patent: 4944941 (1990-07-01), Ammann
patent: 4966843 (1990-10-01), McCormick et al.
patent: 4980455 (1990-12-01), Sakaguchi et al.
patent: 5004689 (1991-04-01), Fiers et al.
patent: 5041376 (1991-08-01), Gething et al.
patent: 5096705 (1992-03-01), Goeddel et al.
patent: 5109120 (1992-04-01), Ueno et al.
patent: 5157004 (1992-10-01), Sakaguchi et al.
patent: 5362490 (1994-11-01), Kurimoto et al.
patent: 5376567 (1994-12-01), McCormick et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5518899 (1996-05-01), Kurimoto et al.
patent: 5541293 (1996-07-01), Stabinsky
patent: 5554515 (1996-09-01), Kurimoto et al.
patent: 5574137 (1996-11-01), Gray et al.
patent: 5582824 (1996-12-01), Goeddel et al.
patent: 5595888 (1997-01-01), Gray et al.
patent: 5661009 (1997-08-01), Stabinsky
patent: 5672692 (1997-09-01), Kurimoto et al.
patent: 5690925 (1997-11-01), Gray et al.
patent: 5711944 (1998-01-01), Gilbert et al.
patent: 5723121 (1998-03-01), Takenaga et al.
patent: 5738846 (1998-04-01), Greenwald et al.
patent: 5747646 (1998-05-01), Hakimi et al.
patent: 5770191 (1998-06-01), Johnson et al.
patent: 5792834 (1998-08-01), Hakimi et al.
patent: 6042822 (2000-03-01), Gilbert et al.
patent: 6046034 (2000-04-01), Waschutza et al.
patent: 6120762 (2000-09-01), Johnson et al.
patent: 6497871 (2002-12-01), Gray et al.
patent: 2096532 (1992-05-01), None
patent: 077 670 (1983-04-01), None
patent: 088 540 (1983-09-01), None
patent: 089 676 (1983-09-01), None
patent: 098 110 (1984-01-01), None
patent: 110 044 (1984-06-01), None
patent: 146 354 (1985-06-01), None
patent: 158 198 (1985-10-01), None
patent: 170 917 (1986-02-01), None
patent: 219 781 (1987-04-01), None
patent: 229 108 (1987-07-01), None
patent: 256 424 (1987-08-01), None
patent: 236 987 (1987-09-01), None
patent: 237 019 (1987-09-01), None
patent: 306 870 (1989-03-01), None
patent: 121 157 (1989-06-01), None
patent: 145 174 (1989-09-01), None
patent: 370 205 (1990-05-01), None
patent: 446 582 (1991-09-01), None
patent: 546 099 (1994-10-01), None
patent: 795 332 (1997-09-01), None
patent: 593 868 (1998-04-01), None
patent: 860 442 (1998-08-01), None
patent: 92/08737 (1991-11-01), None
patent: 92/22310 (1992-06-01), None
patent: 99/03887 (1998-07-01), None
patent: 99/67291 (1999-06-01), None
patent: 01/23006 (2000-09-01), None
patent: 01/36001 (2000-11-01), None
Arakawa, et al. ,Role of Polycationic c-terminal Portion in the Structure and Activity of Recombinant Human Interferon-γ, The Journal of Biological Chemistry, 261(18), Jun. 25, pp. 8534-8539 (1986).
Arakawa, et al.,Structure and Activity of Glycosylated Human Interferon-γ, Journal of Interferon Research, 6:687-695 (1986).
Bulleid, et al.,Source of heterogeneity in secreted interferon-γ, Biochem, J. 268:777-781 (1990).
Cantell, et al.,Differential Inactivation of Interferon by a Protease from Human Granulocytes, Journal of Inerferon Research 12:177-183 (1992).
Castro, et al.,The macroheterogeneity of recombinant human interferon-γ produced by Chinese-hamster ovary cells is affected by the protein and lipid content of the culture medium, Biotechnol. Appl. Biochem., 21:87-100 (1995).
Curling, et al. ,Recombinant human interferon-γ, Differences in glycosylation and proteolytic processing lead to heterogeneity in batch culture, Biochem. J., 272:333-337 (1990).
Devos, et al.,Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells, Nucleic Acids Research, 10(8), 2487-2501, Nov. 8, 1982.
Ealick, et al.,Three-Dimensional Structure of Recombinant Human Interferon-γ, Science, 252:698-702 (1991).
Farrar, et al.,The Molecular Cell Biology of Interferon-γ and its Receptor, Annu. Rev. Immunol. 11:572-611 (1993).
Gray, et al.,Structure of the human immune interferon gene, Nature, 298:859-863 (Aug. 1992).
Griggs, et al.,The N-terminus and C-Terminus of IFNγ Are Binding Domains for Cloned Soluble lFN-γ Receptor, The Journal of Immunology, 149(2) 517-520 (Jul. 15, 1992).
Gu, et al.,Improvement of Interferonγ Sialylation in Chinese Hamster Ovary Cell culture by Feeding of N-Acetylmannosamine, Biotechnology & Bioengineering, 58(6) 642-648 (1998).
Haelewn, et al.,Interaction of truncated human interferon γ variants with the interferon γ receptor: crucial importance of Arg-129, Biochem. J., 324, 591-595 (1997).
Harmon, et al.,Rapid Monitoring of Site-Specific Glycosylation Microheterogeneity of Recombinant Human Interferon-γ, Anal. Chem., 68(9) 1465-1473 (1996).
Hogrefe, et al.,Amino Terminus Is Essential to the Structural Integrity of Recombinant Human Interferon-γ, The Journal of Biological Chemistry, 264(21) 12179-86 (1989).
Hooker, et al.,Constraints on the Transport and Glycosylation of Recombinant IFN-γ in Chinese Hamster Ovary and Insect Cells, Biotechnology & Bioengineering, 63(5) 559-572 (1999).
Hsu, et al.,Structure and activity of Recombinant Human Interferon-γ Analogs, Journal of Interferon Research, 6:663-670 (1986).
James, et al.,N-Glycosylation of Recombinant Human Interferon-γ Produced in Different Animal Expression Systems, Bio/Technology, 13:592-96 (Jun. 13, 1995).
Kita, et al.,Characterization of a Polyethylene Glycol Conjugate of Recombinant Human Interferon-γ, Drug Design and Delivery, 6:157-167 (1990).
Kontsek, et al.,Engineered Acid-Stable Human Interferon Gamma, Cytokine, 12(6) 708-710 (Jun. 2000.
Landar, et al.,Design, Characterization, and Structure of a Biologically Active Single-chain Mutant of Human IFN-γ, J. Mol. Biol., 299:169-179 (2000).
Leinikki, et al.,Reduced Receptor Binding by a Human Interferonγ Fragment Lacking 11 Carboxyl-Terminal Amino Acids, Journal of Immunology, 139(10) 3360-3366 (1987).
Littman, et al.,Binding of Unglycosylated and Glycosylated Human Recombinant Interferon-γ to Cellular Receptors, Journal of Interferon Research, 5: 471-476 (1985).
Lord, et al.,Functional Domains of Human Interferon Gamma Probed With Antipeptide Antibodies, Molecular Immunology, 26(7) 637-640 (1989).
Luk, et al.,Structure-Function Analysis of the Human Interferon γ, The Journal of Biological Chemistry, 265 (22) 13314-13319 (1990).
Lundell, et al.,Importance of the Loop connecting A and B Helices of Human Interferon-γ in Recognition by Interferon-γ Receptor*, The Journal of Biological Chemistry, 269(23) 16159-16162.
Lundell, et al.,Structural Elements Required for Receptor Recognition of Human Interferon-Gamma, Pharmac. Ther. 64:1-21 (1994).
Lundell, et al.,The carboxyl-terminal region of human interferon γ is important for biological activity: mutagenic and NMR analysis, Protein Engineering, 4(3) 335-341 (1991).
Lunn, et al.,A point mutation of human interferon γ abolishes receptor recognition, Protein Engineering, 5(3) 253-257 (1992).
Lunn, et al.,A point mutation that decreases the thermal stability of human interf
Andersen Kim Vilbour
Hansen Christian Karsten
Jensen Anne Dam
Andres Janet L.
Fujita Sharon M.
Kruse Norman J.
Maxygen Holdings Ltd.
Pochopien Donald J.
LandOfFree
Interferon gamma conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interferon gamma conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interferon gamma conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3880620